03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
01:19 , Feb 16, 2018 |  BC Innovations  |  Product R&D

Banking on the placenta

Celgene Corp. spinout Celularity Inc. is aiming to disrupt the stem cell market with a platform of placenta-based cell therapies whose intrinsic allo-tolerance could provide a broadly applicable system for propelling off-the-shelf cancer therapies into...
19:20 , Oct 6, 2017 |  BC Week In Review  |  Company News

WindMIL reveals cell immunotherapy technology

WindMIL Therapeutics Inc. (Baltimore, Md.) emerged from stealth mode to reveal its cell immunotherapy based on bone marrow-derived lymphocytes. The company is evaluating its activated marrow infiltrating lymphocytes (MILs) in a Phase IIb trial alongside...
23:18 , Oct 5, 2017 |  BC Extra  |  Company News

WindMIL delivers bone marrow-derived lymphocytes

WindMIL Therapeutics Inc. (Baltimore, Md.) emerged from stealth mode to reveal its cell immunotherapy based on bone marrow-derived lymphocytes. The company is evaluating its activated marrow infiltrating lymphocytes (MILs) in a Phase IIb trial alongside...
02:34 , Jan 16, 2016 |  BC Extra  |  Clinical News

Calibr researchers propose versatile CAR T strategy

The Scripps Research Institute designed the new T cell constructs to bind a peptide not present in the human body. When co-administered with an antibody switch -- a tumor antigen-binding antibody fragment conjugated to the...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Company News

Juno Therapeutics Inc, Novartis, St. Jude Children’s Research Hospital, University of Pennsylvania deal

Juno granted Novartis a non-exclusive sublicense to chimeric antigen receptor technology targeting CD19 to resolve a patent suit related to U.S. Patent No. 8,399,645, which covers therapeutic uses of chimeric cell membrane receptors. St. Jude...
00:22 , Apr 7, 2015 |  BC Extra  |  Company News

Juno settles CAR T patent suit with Novartis, UPenn

Juno Therapeutics Inc. (NASDAQ:JUNO) settled litigation with Novartis AG (NYSE:NVS; SIX:NOVN) and the University of Pennsylvania related to U.S. Patent No. 8,399,645. Juno's partner St. Jude Children's Research Hospital owns the patent, which covers therapeutic...
07:00 , Jun 26, 2014 |  BC Innovations  |  Cover Story

Keys to the CAR

Although companies, investors and academics are all racing to develop chimeric antigen receptor-based T cells for cancer, numerous basic science questions still surround the technology. The way forward will likely involve combining chimeric antigen receptors...
08:00 , Feb 8, 2010 |  BioCentury  |  Product Development

Checking the boxes in gene therapy

Amsterdam Molecular Therapeutics thinks its Glybera represents the right combination of vector, gene and disease setting to become the first gene therapy to be approved outside of China. The European Medicines Agency now has accepted...